Donate

Publication

Improving target assessment in biomedical research: the GOT-IT recommendations

Citation:
Nature Reviews Drug Discovery 2021; 20: 64–81 https://doi.org/10.1038/s41573-020-0087-3
Authored By:
Emmerich, C.H., Gamboa, L.M., Hofmann, M.C.J. Marc Bonin-Andresen, Olga Arbach, Pascal Schendel, Björn Gerlach, Katja Hempel, Anton Bespalov, Ulrich Dirnagl & Michael J. Parnham
Abstract:
Academic research plays a key role in identifying new drug targets, including understanding target biology and links between targets and disease states. To lead to new drugs, however, research must progress from purely academic exploration to the initiation of efforts to identify and test a drug candidate in clinical trials, which are typically conducted by the biopharma industry. This transition can be facilitated by a timely focus on target assessment aspects such as target-related safety issues, druggability and assayability, as well as the potential for target modulation to achieve differentiation from established therapies. Here, we present recommendations from the GOT-IT working group, which have been designed to support academic scientists and funders of translational research in identifying and prioritizing target assessment activities and in defining a critical path to reach scientific goals as well as goals related to licensing, partnering with industry or initiating clinical development programmes. Based on sets of guiding questions for different areas of target assessment, the GOT-IT framework is intended to stimulate academic scientists’ awareness of factors that make translational research more robust and efficient, and to facilitate academia–industry collaboration.
Published in:
Nature Reviews Drug Discovery
View article

More Publications

May 19, 2023

Nature Reviews Neurology

Global synergistic actions to improve brain health for human development

View
April 20, 2023

Nature Mental Health

Machine learning-based identification of a psychotherapy-predictive electroencephalographic signature in PTSD

View
February 13, 2023

Frontiers in Aging Neuroscience

Machine learning within the Parkinson’s progression markers initiative: Review of the current state of affairs

View
September 9, 2022

Sensors

Deep Learning for Daily Monitoring of Parkinson’s Disease Outside the Clinic Using Wearable Sensors

View
June 1, 2022

JAMA Network Open

Association of Posttraumatic Stress Disorder With Accelerated Cognitive Decline in Middle-aged Women

View
March 23, 2022

Journal of Neurotrauma

A Framework to Advance Biomarker Development in the Diagnosis, Outcome Prediction, and Treatment of Traumatic Brain Injury

View
View All

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

©2023 Cohen Veterans Bioscience |  Privacy Policy | Terms of Use

Newsletter
Donate